UCLA Hematology/Oncology - Alhambra

Alhambra, California 91801

1 studies enrolling now · 8 studies all time

What they study most

Advanced Solid Tumors, Breast Cancer, Cancer, Cancer of the Prostate, HER2 Positive Breast Cancer, HER2-positive Breast Cancer, Hormone Sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Non-Small Cell Lung Cancer, Prostate Cancer, Urothelial Carcinoma

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• Open-Label Extension and Safety Study of Talazoparib — Completed
• An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) — Completed
• Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer — Completed
• ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer — Completed